Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Am J Obstet Gynecol. 2017 Jan 5;216(5):500.e1–500.e11. doi: 10.1016/j.ajog.2016.12.177

Table 3.

Number of AEs by SIR Class for All Patients in the CCD

SIR Class and AE Categorya MRgFUS
(n=43)
UAE
(n=40)
Class D (major therapy, unplanned increase in
  level of care, prolonged hospitalization)
2 2
    Surgical treatment within 6 wk 2 0
    Rehospitalization (≥48 h) 0 1
    Postembolization syndrome 0 1
Class C (required therapy, minor
  hospitalization)
1 2
    Rehospitalization (<48 h) 0 2
    Other: urinary retention requiring
      catheterization
1 0
Class B (nominal therapy, observation, no
  consequences)
11 13
    Postembolization syndrome 0 2
    Severe/prolonged pain 3 1
    Vaginal passage of leiomyoma tissue 1 3
    Peripheral nerve injury: sacral neuropathy 2 0
    Urinary tract infection 3 1
    Allergic reaction/rash 1 2
    Other 1 4
Class A (no therapy, no consequences) 13 5
    Severe/prolonged pain 2 0
    Vaginal passage of leiomyoma tissue 1 0
    Peripheral nerve injury 3 0
        Upper/lower extremity tingling 2
        Sacral neuropathy 1
    Urinary tract infection 1 0
    Allergic reaction/rash 2 0
    Other 4 5

Abbreviations: AE, adverse event; CCD, comprehensive cohort design; MRgFUS, magnetic resonance imaging–guided ultrasound surgery; SIR, Society of Interventional Radiology; UAE, uterine artery embolization.

a

No AEs of class F (death) or E (permanent adverse sequelae) occurred in the CCD cohort.